1. Home
  2. BLLN vs FOLD Comparison

BLLN vs FOLD Comparison

Compare BLLN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$92.70

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.30

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
FOLD
Founded
2016
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.4B
IPO Year
2025
2007

Fundamental Metrics

Financial Performance
Metric
BLLN
FOLD
Price
$92.70
$14.30
Analyst Decision
Buy
Buy
Analyst Count
6
10
Target Price
$137.83
$26.11
AVG Volume (30 Days)
222.9K
8.1M
Earning Date
12-09-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$254,136,000.00
$598,704,000.00
Revenue This Year
$98.01
$21.49
Revenue Next Year
$36.76
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
254.30
21.28
52 Week Low
$80.00
$5.51
52 Week High
$138.70
$14.38

Technical Indicators

Market Signals
Indicator
BLLN
FOLD
Relative Strength Index (RSI) 55.02 78.81
Support Level $80.65 $14.30
Resistance Level $87.54 $14.31
Average True Range (ATR) 5.60 0.03
MACD 0.97 -0.12
Stochastic Oscillator 88.21 35.00

Price Performance

Historical Comparison
BLLN
FOLD

About BLLN BillionToOne Inc.

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: